BMY obtains CHMP recommendation for Opdivo for perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by ...

Seven-year follow-up data of a multicenter, randomized phase 2 study evaluating the treatment of melanoma brain metastases shows ipilimumab plus nivolumab is an effective long-term care option. First ...

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

Candel Therapeutics (CADL) announced the publication of a manuscript reporting the results of a phase 1b clinical trial exploring safety and ...

During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant ...

The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among certain patients with breast cancer, according to findings published in Nature Medicine ...

Our data clearly show that it is feasible and safe to implement stepwise acceleration of nivolumab and pembrolizumab administration to a 10-minute infusion time,” the researchers wrote.

During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations ...

BeyondSpring Inc.’s BYSI share price has surged by 12.89%, which has investors questioning if this is right time to sell.

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.

Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...